Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pharmacology|April 19, 2017
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation ApproachWan Sun, Peter J O'Dwyer, Richard S Finn, et al.
Journal of Clinical Pharmacology|December 3, 2013
A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteersAna Ruiz-Garcia, Nagdeep Giri, Robert R LaBadie, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2012
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in studyGeorge R Blumenschein, Tudor Ciuleanu, Francisco Robert, et al.
Cancer Chemotherapy and Pharmacology|December 9, 2010
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsElisabeth I Heath, George R Blumenschein, Roger B Cohen, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 31, 2021
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumabNadia Terranova, Jonathan French, Haiqing Dai, et al.
Lung Cancer (Amsterdam, Netherlands)|March 2, 2010
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation studyMartin Reck, Norbert Frickhofen, Susana Cedres, et al.
Journal of Clinical Pharmacology|July 17, 2015
Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteersAna Ruiz-Garcia, Joanna C Masters, Laure Mendes da Costa, et al.
Investigational New Drugs|August 22, 2013
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation studyNormand Blais, D Ross Camidge, Derek J Jonker, et al.
Investigational New Drugs|January 18, 2012
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumorsToshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, et al.
Cancer Chemotherapy and Pharmacology|October 31, 2012
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesotheliomaD Ross Camidge, Normand Blais, Derek J Jonker, et al.
Pageof 4